Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/05/2003CA2467966A1 Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma
06/05/2003CA2467874A1 N-ureido-piperidines as antagonists viii for ccr-3 receptor
06/05/2003CA2467825A1 Benzothiazole derivatives
06/05/2003CA2467734A1 Composition based on diosgenin ester for topical use
06/05/2003CA2467677A1 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
06/05/2003CA2467664A1 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
06/05/2003CA2467645A1 Composition for removing fibrin-bound blood clots from a catheter
06/05/2003CA2467565A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
06/05/2003CA2467451A1 Method for controlling angiogenesis in animals
06/05/2003CA2467165A1 Therapeutic compounds for treating dyslipidemic conditions
06/05/2003CA2466870A1 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003CA2466867A1 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003CA2466864A1 Treatment of neovascular ophthalmic disease
06/05/2003CA2466863A1 Formulations for oral administration of cromolyn sodium
06/05/2003CA2466845A1 Manipulation of cytokine levels using cd83 gene products
06/05/2003CA2466807A1 Pharmaceutical formulations comprising indolinone derivatives
06/05/2003CA2466677A1 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
06/05/2003CA2465846A1 Targeted therapeutics and uses thereof
06/05/2003CA2463592A1 Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
06/05/2003CA2461816A1 Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties
06/04/2003EP1316562A2 Composition comprising a covalent polyethylene glycol (PEG)-protein adduct
06/04/2003EP1316552A1 Processing method of lactonization in the preparation of statins
06/04/2003EP1316551A1 Process for preparing epoxy compounds, aromatic compositions containing the compounds, and drinks, perfumes, cosmetics, cigarettes, and tobaccos containing the compositions
06/04/2003EP1316549A1 1-benzyl-4- (5,6-dimethoxy-2-fluoro-1-indanon)-2-yl] methylpiperidine
06/04/2003EP1316548A1 Acylsulfonamide derivatives
06/04/2003EP1316317A1 Hydrosoluble mixtures of cyproterone and/or an ester of it, processes to obtain them and uses thereof
06/04/2003EP1316316A1 Preparations for oral administration
06/04/2003EP1316313A2 Composition for the treatment of ischemic stroke containing zonampanel and a tissue plasminogen activator
06/04/2003EP1316311A1 Therapeutic use on-demand of formoterol and budesonide
06/04/2003EP1316310A1 Ophthalmic composition comprising a histidine derivative for healing asthenopia
06/04/2003EP1316309A1 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
06/04/2003EP1316308A1 Transdermal therapeutic device with capsaicin and capsaicin analogs
06/04/2003EP1316306A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316305A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316304A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316303A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316302A1 Cosmetic and/or dermatological composition containing at least one oxidation sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316301A1 Cosmetic or dermatological composition containing a retinoid and/or a carotenoid and acexamic acid
06/04/2003EP1316203A2 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
06/04/2003EP1315965A2 Methods and compositions for in vitro targeting
06/04/2003EP1315963A1 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
06/04/2003EP1315840A2 Biopanning and rapid analysis of selective interactive ligands (brasil)
06/04/2003EP1315837A2 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
06/04/2003EP1315831A2 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
06/04/2003EP1315830A2 Compositions and methods for targeting peptides in humans in vivo
06/04/2003EP1315807A2 Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides
06/04/2003EP1315755A1 Anti-angiogenic peptides
06/04/2003EP1315741A2 A method for treating allergies
06/04/2003EP1315736A2 Nucleoside derivatives for the treatment of hepatitis c
06/04/2003EP1315735A1 Phosphate derivatives as immunoregulatory agents
06/04/2003EP1315731A1 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
06/04/2003EP1315730A1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives
06/04/2003EP1315729A1 Compounds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated diseases or dysfunction
06/04/2003EP1315728A1 Process for the preparation of vitronectin receptor antagonists
06/04/2003EP1315727A2 7-oxo pyridopyrimidines
06/04/2003EP1315726A1 7- oxo pyridopyrimidines as inhibitors of cellular proliferation
06/04/2003EP1315725A1 Bicyclic enamide derivatives being integrin inhibitors
06/04/2003EP1315724A1 A thiazolidinedione derivative and its use as antidiabetic
06/04/2003EP1315723A1 The hydrochloride salt of 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
06/04/2003EP1315722A1 Thiazolidinone nitrate salt
06/04/2003EP1315721A1 A thiazolidinedione derivative and its use as antidiabetic
06/04/2003EP1315720A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315719A1 Multivalent neuraminidase inhibitor conjugates
06/04/2003EP1315718A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315717A1 Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315716A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315715A1 Quinazoline derivatives as kinase inhibitors
06/04/2003EP1315714A2 Quinazoline derivatives as alpha-1 adrenergic antagonists
06/04/2003EP1315710A1 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
06/04/2003EP1315709A1 Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
06/04/2003EP1315708A1 Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
06/04/2003EP1315705A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
06/04/2003EP1315704A1 2-guanidino-4-aryl-quinazoline
06/04/2003EP1315703A1 Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
06/04/2003EP1315700A2 Substituted 4-phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
06/04/2003EP1315698A1 Pyrrolidines as inhibitors of neuraminidases
06/04/2003EP1315695A2 Benzene tricarboxylic acid amides as insulin receptor activators
06/04/2003EP1315694A2 Inhibitors of alpha 4 mediated cell adhesion
06/04/2003EP1315691A1 Method of obtaining a hydroxytyrosol-rich composition from vegetation water
06/04/2003EP1315672A1 Delivery vehicle composition and methods for delivering antigens and other drugs
06/04/2003EP1315571A1 Concentric tubular centrifuge
06/04/2003EP1315539A2 Antithrombotic compositions
06/04/2003EP1315521A2 Method for improving the efficacy of artificial insemination of non-human animals
06/04/2003EP1315512A2 Adenoviral targeting and manipulation of immune system response using targeting peptides
06/04/2003EP1315509A2 Treatment of drug resistant organisms with nitric oxide
06/04/2003EP1315508A1 Purine ribosides as antiarrhythmics
06/04/2003EP1315507A2 Hpv-specific short-mers
06/04/2003EP1315506A2 Phospholipid derivatives of valproic acid and mixtures thereof
06/04/2003EP1315505A2 Pharmaceutical compositions for headache, migraine, nausea and emesis
06/04/2003EP1315504A1 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
06/04/2003EP1315503A1 Treatment of urinary dysfunction
06/04/2003EP1315502A1 Method for treating erectile dysfunction and increasing libido in men
06/04/2003EP1315501A1 Alpha v integrin receptor antagonists
06/04/2003EP1315500A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
06/04/2003EP1315499A1 Compositions and methods for the treatment of anorectal disorders
06/04/2003EP1315498A2 Use of ectoin or ectoin derivatives for stabilizing p53
06/04/2003EP1315497A2 Amino derivatives of 2,3-dihydrophtalazine-1,4-dione as immunocorrecting agents
06/04/2003EP1315496A2 The treatment of inflammatory disorders
06/04/2003EP1315495A2 Use of threo-methylphenidate compounds to enhance memory
06/04/2003EP1315494A1 Agent for modulating excitatory synaptic transmission comprising a compound having alpha-7 nicotinic acetylcholine receptor activation property
1 ... 5447 5448 5449 5450 5451 5452 5453 5454 5455 5456 5457 5458 5459 5460 5461 5462 5463 5464 5465 5466 5467 ... 7860